Resource Library
Achieving Accelerated Tech Transfer for a COVID-19 Program: Development to Manufacturing
Technology transfer is a critical step along the path to the large-scale production of COVID-19 therapeutics, but its highly complex nature makes it time-consuming. In this whitepaper, Andrew Kim, our Associate Director of Downstream MSAT, explains how accelerating tech transfer without sacrificing quality demands strong communication, operational agility, early investment in critical path items, and continuous risk management. As a trusted CDMO partner, Samsung Biologics has successfully accelerated tech transfer down to three to five months for clients developing COVID-19 therapies.
Technology transfer is a critical step along the path to the large-scale production of COVID-19 therapeutics, but its highly complex nature makes it time-consuming. In this whitepaper, Andrew Kim, our Associate Director of Downstream MSAT, explains how accelerating tech transfer without sacrificing quality demands strong communication, operational agility, early investment in critical path items, and continuous risk management. As a trusted CDMO partner, Samsung Biologics has successfully accelerated tech transfer down to three to five months for clients developing COVID-19 therapies.